论文部分内容阅读
目的观察阿奇霉素联合孟鲁司特治疗小儿支原体肺炎的临床疗效。方法选取支原体肺炎患儿84例,随机分为观察组和对照组各42例。对照组予常规治疗,观察组在对照组治疗基础上加用孟鲁司特治疗,观察、比较2组疗效及不良反应发生情况。结果观察组总有效率97.62%,高于对照组的80.95%(χ2=6.0978,P<0.05)。2组患儿胃肠反应、皮疹、食欲不振及头晕头痛等不良反应发生率比较差异无统计学意义(P>0.05)。结论阿奇霉素联合孟鲁司特治疗小儿支原体肺炎,临床疗效肯定,安全性高。值得临床推广应用。
Objective To observe the clinical efficacy of azithromycin and montelukast in the treatment of children with mycoplasma pneumonia. Methods 84 cases of children with mycoplasma pneumonia were randomly divided into observation group and control group, 42 cases each. The control group was given routine treatment. The observation group was treated with montelukast on the basis of the control group. The curative effect and adverse reactions of the two groups were observed and compared. Results The total effective rate in observation group was 97.62%, which was higher than 80.95% in control group (χ2 = 6.0978, P <0.05). The incidence of gastrointestinal reactions, rash, loss of appetite and dizziness, headache and other adverse reactions in the two groups showed no significant difference (P> 0.05). Conclusion Azithromycin combined with montelukast treatment of children with mycoplasma pneumonia, positive clinical effect, high safety. Worthy of clinical application.